- The trend backdrop is active with a 35-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
BRM
GER
Week ended 31 Jul 2026
Weekly Investor Report
Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General
Latest close
56.16 EUR
2.9%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 12.1% above the Trend Line and sits at 94.0% of its 52-week range. The latest completed week returned 2.9%, after a 12.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high.
Setup score
79
out of 100
Latest Close
56.16 EUR
31 Jul 2026
1W Return
2.9%
latest completed week
4W Return
12.2%
short-term follow-through
12W Return
17.5%
quarterly tape
Trend Breadth
67.3%
35 of 52 weeks active
Volume Ratio
2.9x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.9%
Latest completed week; four-week move 12.2%.
Indicator stack
82/73
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
11 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 12.1% above the Trend Line and sits at 94.0% of its 52-week range. The latest completed week returned 2.9%, after a 12.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6312-week average 0.66
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.63Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 12.2% over four weeks, 17.5% over 12 weeks, and 54.9% over one year. The current trend has remained active for 35 consecutive weeks.
Performance by holding period
Active trend streak35 weeks
Active weeks in one year35
Trend breadth67.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.60Latest activity-pressure read.
Pressure change158.0%Four-week change in activity pressure.
Leadership16.59Latest relative-leadership reading.
RS change190.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 87%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength93/100Blend of value, momentum, and quality. Underlying universe rank 8; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth31/100Revenue and earnings growth. Underlying universe rank 70; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework84/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 15.3x Price divided by trailing earnings.
- Price / sales
- 2.3x Market value relative to trailing revenue.
- EV / EBITDA
- 9.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 8.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 70.5% Gross profit retained from each unit of revenue.
- Operating margin
- 28.0% Operating profit retained from revenue.
- Free-cash-flow margin
- 24.6% Free cash flow generated from revenue.
- Return on invested capital
- 17.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -0.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -7.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 8/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 4.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 4.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 11 relevant articles.
2 positive · 9 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-2.3%Distance below the 52-week high.
13-week volatility4.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher17 of 269 weeks finished lower.
Best week+12.6%Week of 6 Feb.
Worst week-7.1%Week of 8 May.
Latest week+2.9%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains13
Flat weeks0
Modest losses7
Sharp losses2
Recent vol4.1%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -2.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank6 / 78
Group average-0.2%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD67.9%positive activity pressure
RS37.2%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - General
4-week rank1 / 12
Group average-1.0%
Trend breadth58.3%
Trend58.3%active weekly trend signals
MD83.3%positive activity pressure
RS75.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape76/100
Trend, activity pressure, participation, and risk combine to a 76/100 tape read.
Indicator analysis63/100Latest 12-week confirmation: trend 12/12, activity pressure 2/12, relative leadership 12/12.
Activity pressure 0.63; 2 reversal markers Factors83/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 58 SVQF84/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 61.0 of 372 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 11 relevant articles.
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 56.16 EUR | 2.9% | 50.10 EUR | 44.02 EUR | 0.60 | 16.59 | 12.4K | On |
| 24 Jul 2026 | 54.57 EUR | 0.8% | 49.74 EUR | 43.97 EUR | 0.12 | 16.45 | 3.0K | On |
| 17 Jul 2026 | 54.13 EUR | 7.8% | 49.41 EUR | 43.92 EUR | -0.25 | 17.45 | 5.0K | On |
| 10 Jul 2026 | 50.20 EUR | 0.3% | 49.11 EUR | 43.90 EUR | -0.79 | 8.53 | 6.0K | On |
| 3 Jul 2026 | 50.07 EUR | 0.7% | 48.89 EUR | 43.88 EUR | -1.03 | 5.71 | 4.4K | On |
| 26 Jun 2026 | 49.71 EUR | 5.1% | 48.69 EUR | 43.88 EUR | -1.21 | 10.04 | 1.1K | On |
| 19 Jun 2026 | 47.28 EUR | -2.9% | 48.40 EUR | 43.88 EUR | -1.31 | 3.83 | 375 | On |
| 12 Jun 2026 | 48.67 EUR | -1.4% | 48.13 EUR | 43.91 EUR | -1.08 | 8.67 | 616 | On |
| 5 Jun 2026 | 49.37 EUR | 1.7% | 47.82 EUR | 43.93 EUR | -1.06 | 9.94 | 2.4K | On |
| 29 May 2026 | 48.55 EUR | -5.2% | 47.49 EUR | 43.94 EUR | -1.01 | 7.03 | 3.3K | On |
| 22 May 2026 | 51.24 EUR | 5.8% | 47.17 EUR | 43.97 EUR | -0.80 | 14.26 | 6.5K | On |
| 15 May 2026 | 48.44 EUR | 1.4% | 46.69 EUR | 43.97 EUR | -0.77 | 12.74 | 4.0K | On |
| 8 May 2026 | 47.78 EUR | -7.1% | 46.28 EUR | 44.00 EUR | -0.52 | 9.87 | 7.1K | On |
| 1 May 2026 | 51.45 EUR | 3.0% | 45.92 EUR | 44.03 EUR | -0.38 | 18.89 | 3.7K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.